{ "items": [ "\n\n
\n \n 3 February 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 3 February 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 3 February 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 3 February 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 30 January 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 9 August 2018\n \n
\n\n \n \n \n\n \n \n \nThe Medical Sciences Divisional Panel has conferred the title of Professor on Associate Professor Simon Draper and the title of Associate Professor on Dr Teresa Lambe, Dr George Warimwe and Dr David Wyllie. They have all been awarded these titles in recognition of their distinction in their respective fields and contributions to the research, teaching and administration of the Department and we congratulate them on their success.
\n \n\n\n \n 2 July 2018\n \n
\n\n \n \n \n\n \n \n \nThe malaria parasite is a shape-shifter, changing its surface coat to escape destruction by the human body. This depends upon a malaria protein called RH5 binding to a human protein called basigin on the surface of red blood cells. Unlike the other variable malaria surface proteins, RH5 does not vary, making it more easily recognised and destroyed. Jenner Investigators Sumi Biswas and Simon Draper have immunised human volunteers with RH5. Antibodies isolated from these volunteers prevent the parasite from invading red blood cells. At the RS Summer Science Exhibition they will show the public how it works, using games to detect the unchanging elements in a shape-shifting parasite, 3D models demonstrating of RH5 binding to basigin and antibodies and interactive maps to see the impact of vaccines on global health.
\n \n\n\n \n 25 May 2018\n \n
\n\n \n \n \n\n \n \n \nNucleic acids are one of the most fundamental units of biological research. The genes coded for in DNA or RNA, translated by and expressed via other RNAs are integral to many research projects.
\n \n\n\n \n 25 April 2018\n \n
\n\n \n \n \n\n \n \n \nJenner researcher Dr Teresa Lambe has joined the University's new Innovation Champions initiative. As a Champion, Teresa will help improve the landscape for innovation and entrepreneurial activities within the Medical Sciences Division. Champions act as a first point of contact for colleagues interested in commercialising their ideas or expertise, or developing links with industry, whether through consulting or research collaboration.
\n \n\n\n \n 17 January 2018\n \n
\n\n \n \n \n\n \n \n \nWe were all very saddened to hear the news that Bonnie Mathieson passed away on January 8th 2018. Bonnie made many contributions to vaccine research and especially to HIV vaccine development, and served as a member of the Jenner Institute\u2019s Scientific Advisory Board.
\n \n\n\n \n 3 November 2017\n \n
\n\n \n \n \n\n \n \n \nA new report is being released today that unveils 50 female leaders in healthcare business in the UK, which includes Jenner Investigator Professor Sumi Biswas. Produced by BioBeat, 50 Movers and Shakers in BioBusiness 2017 emphasises how diversity of thinking is critical to the success of the sector in the UK, which also celebrates how women are driving innovation in healthcare.
\n \n\n\n \n 3 October 2017\n \n
\n\n \n \n \n\n \n \n \nResearchers are seeking about 500 NHS patients to try out a new \"universal\" vaccine against seasonal flu. The experimental vaccine works differently from the one currently available, which has to be remade each year based on a \"best guess\" of what type of flu is likely to be about.\r\n\r\nThe new jab targets part of the virus that does not change each year. This means the vaccine should work against human, bird and swine flu, say the team from the University of Oxford led by Prof Sarah Gilbert, Jenner Investigator.
\n \n\n\n \n 26 July 2017\n \n
\n\n \n \n \n\n \n \n \n\u2018We started the first trial in 2002 and we finished the efficacy trial in 2013.\u2019 Nine years of trials. That was on top of the time taken to develop the thing in the first place. That\u2019s a long time. For Le Mans, the MdS and the Vendee Globe, the finish line is known, fixed; for vaccines, new data may move the finish line at any time. Vaccine development may not be as physically demanding, but to keep plugging away for twenty years surely requires mental resilience.
\n \n\n\n \n 26 July 2017\n \n
\n\n \n \n \n\n \n \n \nJenner scientist Dr Rachel Tanner has been awarded an NC3Rs Skills and Knowledge Transfer Grant for the transfer of a novel non-human primate in vitro mycobacterial growth inhibition assay. The assay will be transferred to Public Health England and the Biomedical Primate Research Centre, with the aim of refining and reducing use of non-human primate TB infection models in the early evaluation of TB vaccine candidates.
\n \n\n\n \n 7 June 2017\n \n
\n\n \n \n \n\n \n \n \nStatement from Professor Ewan McKendrick, Registrar of Oxford University, regarding BBC\u2019s File on 4 programme (6 June 2017) examining the role of animal experiments in the development of a new human vaccine for tuberculosis.
\n \n\n\n \n 30 May 2017\n \n
\n\n \n \n \n\n \n \n \nWhether a painful strep throat turns into a fatal case of heart disease depends not just on prompt antibiotic treatment but also on the patient\u2019s genetic makeup, according to a new study led by Oxford University scientists. The discovery could help the long fight to find a vaccine against Group A streptococcus bacteria, which cause strep throat, scarlet fever and rheumatic heart disease. The Oxford study, published in Nature Communications this month, was done in Fiji, New Caledonia and other South Pacific islands \u201cbecause it\u2019s one of the top reasons young people die there,\u201d said Dr. Tom Parks, lead author and part of Prof Adrian Hill's genetics group which studies genetic susceptibility to infectious diseases.
\n \n\n\n \n 22 May 2017\n \n
\n\n \n \n \n\n \n \n \nA new partnership has been formed between European and African researchers to develop an AIDS vaccine that can be used to prevent infection with different strains of HIV worldwide. The partnership, which is led by Prof Tom\u00e1\u0161 Hanke at the Jenner Institute, will evaluate a new vaccine that triggers the body to produce T-cells, at four sites in Kenya, Uganda and Zambia. Professor Tom\u00e1\u0161 Hanke said: 'There is enormous variation between HIV strains worldwide, which as well as making treatment difficult, has also been an obstacle to developing a vaccine. By using small parts common to most HIV strains, if successful, the vaccine could be used around the world, especially in Africa which is most affected by the HIV pandemic.'
\n \n\n\n \n 2 May 2017\n \n
\n\n \n \n \n\n \n \n \np53 is one of the most damaged genes in cancer. Because p53 stays inside the cells, it is not straightforward to identify and kill the cells with damaged p53. Jenner Institute researcher, Dr Nicola Ternette has developed an antibody that recognises a p53 fragment presented on cancer cell surface and shows in a recent publication that this antibody is a promising new drug for cancer immunotherapy.
\n \n\n\n \n 31 March 2017\n \n
\n\n \n \n \n\n \n \n \nAn Oxford University spinout company is developing a molecular superglue for the rapid development of vaccines targeting a range of diseases. SpyBiotech, co-founded by Jenner researchers Sumi Biswas, Jing Jin and Simon Draper aims to facilitate the rapid development of robust and novel vaccines.
\n \n\n\n \n 15 March 2017\n \n
\n\n \n \n \n\n \n \n \nThe tenth anniversary of the European Research Council (ERC) has been marked by a series of events and a video featuring some of Oxford's recipients of ERC funding. In a video to mark the anniversary, a number of Oxford University academics have explained how ERC funding has been vital to their research, including Adrian Hill, Director of the Jenner Institute.
\n \n\n